These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9829525)

  • 21. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
    Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartûsková J; Válek A
    Czech Med; 1990; 13(2-3):98-106. PubMed ID: 2245762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous erythropoietin: a comparison of daily and thrice weekly administration.
    Granolleras C; Branger B; Shaldon S; Nonnast-Daniel B; Koch KM; Pollok M; Baldamus CA
    Contrib Nephrol; 1991; 88():144-8; discussion 149-51. PubMed ID: 2040176
    [No Abstract]   [Full Text] [Related]  

  • 23. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: a multicenter trial.
    Schaller R; Sperschneider H; Thieler H; Dutz W; Hans S; Voigt D; Marx M; Engelmann J; Schöter KH; Scigalla P
    Artif Organs; 1994 Aug; 18(8):552-8. PubMed ID: 7993190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous erythropoietin therapy: efficacy and economic implications.
    Kaufman JS
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S147-51. PubMed ID: 9892382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
    Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
    Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
    Lui SF; Wong KC; Li PK; Lai KN
    Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients.
    Albitar S; Meulders Q; Hammoud H; Soutif C; Bouvier P; Pollini J
    Nephrol Dial Transplant; 1995; 10 Suppl 6():40-3. PubMed ID: 8524493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The treatment of anemia with low-dose recombinant human erythropoietin.
    Aronoff GR; Duff DR; Sloan RS; Brier ME; Maurice B; Erickson B; Golper TA
    Am J Nephrol; 1990; 10 Suppl 2():40-3. PubMed ID: 2260617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous erythropoietin in the treatment of renal anaemia.
    Drinovec J; Varl J
    Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
    Abreo K; Lubom JA; Collier L; Fleming D; Work J
    Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME; Fragale MR
    Am J Nephrol; 1994; 14(1):14-8. PubMed ID: 8017476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration.
    Zehnder C; Blumberg A
    Nephron; 1991; 57(4):485-6. PubMed ID: 2046836
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.
    Winearls CG
    Drugs; 1989 Sep; 38(3):342-5. PubMed ID: 2806134
    [No Abstract]   [Full Text] [Related]  

  • 34. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.).
    De Schoenmakere G; Lameire N; Dhondt A; Van Loo A; Van der Goten J; Duym P; Vanholder R
    Nephrol Dial Transplant; 1998 Jul; 13(7):1770-5. PubMed ID: 9681726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin].
    Boratyńska M; Mazanowska O; Szewczyk Z
    Pol Merkur Lekarski; 1996 Nov; 1(5):329-31. PubMed ID: 9273209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to EPO therapy.
    Bommer J
    Przegl Lek; 1992; 49(1-2):36-7. PubMed ID: 1455003
    [No Abstract]   [Full Text] [Related]  

  • 37. Continuous intravenous intradialysis versus intravenous postdialysis erythropoietin therapy in chronic haemodialysis patients: a randomized, controlled, crossover study.
    Rocha JL; Gentil MA; Gili M; Gil L; Cabello V; Bernal G
    Nephrol Dial Transplant; 1998 Jan; 13(1):89-92. PubMed ID: 9481721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin.
    McMahon LP; Dawborn JK
    Am J Nephrol; 1990; 10(5):404-8. PubMed ID: 2080791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of intravenous and subcutaneous erythropoietin in patients on hemodialysis and continuous ambulatory peritoneal dialysis.
    Lai PC; Wu MS; Huang JY; Huang CC; Leu ML
    Changgeng Yi Xue Za Zhi; 1994 Jun; 17(2):105-12. PubMed ID: 8069732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The practical aspects of therapy with rHuEPO.
    Spinowitz B
    Am J Nephrol; 1990; 10 Suppl 2():24-8. PubMed ID: 2260614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.